AKT1 and ovarian cancer: We then showed that the new anti-AMH antibody B10 can reduce cell viability, clonogenic survival, and AKT phosphorylation in four ovarian cancer cell lines (Fig. 2) and also in tumor cells isolated from ovarian cancer ascites samples (Fig. 3).